Are ACE inhibitors and ARBs more beneficial than harmful in the treatment of severe COVID-19 disease?
<p>After starting in China four months ago, the COVID-19 pandemic now affects most countries and has already caused more than 200,000 deaths by April 26, 2020</p><p>Under chest computerized tomography scans, the majority of severe COVID-19 patients show bilateral ground glass-like...
Saved in:
Main Author: | Christian A Devaux (Author) |
---|---|
Format: | Book |
Published: |
Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications,
2020-05-05.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
by: Geert Byttebier, et al.
Published: (2021) -
Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?
by: Cody Carson, et al.
Published: (2016) -
Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
by: Elena Raccuglia, et al.
Published: (2009) -
Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study
by: Ahmed A. Alrashed, et al.
Published: (2021) -
Student Evaluation of Teaching: More Harm than Good?
by: M. O. Abramova, et al.
Published: (2023)